Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2013-12, Vol.27 (12), p.2422-2424
Hauptverfasser:	Zamarin, D, Devlin, S M, Arcila, M E, Landau, H, Lesokhin, A, Lendvai, N, Chung, D J, Chimento, D, Weltz, J, Babu, D, Giralt, S, Hassoun, H
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/2325 631/67/1990/804 692/700/1750 Biopsy Bone marrow Cancer Research Cell cycle Critical Care Medicine Drug therapy Hematology Humans Immune response Immunologic Factors - therapeutic use Immunosuppression Incidence Intensive Internal Medicine Investigations letter-to-the-editor Letters to the editor Leukemia Medicine Medicine & Public Health Missing data Multiple myeloma Multiple Myeloma - complications Multiple Myeloma - drug therapy Multiple Myeloma - immunology Oncology Plasmacytosis Prognosis Thalidomide - analogs & derivatives Thalidomide - therapeutic use Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!